Cargando…

In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo

BACKGROUND: Between 2009 and 2012, malaria cases diagnosed in a Médecins sans Frontières programme have increased fivefold in Baraka, South Kivu, Democratic Republic of the Congo (DRC). The cause of this increase is not known. An in vivo drug efficacy trial was conducted to determine whether increas...

Descripción completa

Detalles Bibliográficos
Autores principales: de Wit, Marit, Funk, Anna L., Moussally, Krystel, Nkuba, David Aksanti, Siddiqui, Ruby, Bil, Karla, Piriou, Erwan, Bart, Aldert, Bahizi Bizoza, Patrick, Bousema, Teun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013565/
https://www.ncbi.nlm.nih.gov/pubmed/27599612
http://dx.doi.org/10.1186/s12936-016-1444-x
_version_ 1782452190501142528
author de Wit, Marit
Funk, Anna L.
Moussally, Krystel
Nkuba, David Aksanti
Siddiqui, Ruby
Bil, Karla
Piriou, Erwan
Bart, Aldert
Bahizi Bizoza, Patrick
Bousema, Teun
author_facet de Wit, Marit
Funk, Anna L.
Moussally, Krystel
Nkuba, David Aksanti
Siddiqui, Ruby
Bil, Karla
Piriou, Erwan
Bart, Aldert
Bahizi Bizoza, Patrick
Bousema, Teun
author_sort de Wit, Marit
collection PubMed
description BACKGROUND: Between 2009 and 2012, malaria cases diagnosed in a Médecins sans Frontières programme have increased fivefold in Baraka, South Kivu, Democratic Republic of the Congo (DRC). The cause of this increase is not known. An in vivo drug efficacy trial was conducted to determine whether increased treatment failure rates may have contributed to the apparent increase in malaria diagnoses. METHODS: In an open-randomized non-inferiority trial, the efficacy of artesunate–amodiaquine (ASAQ) was compared to artemether–lumefantrine (AL) for the treatment of uncomplicated falciparum malaria in 288 children aged 6–59 months. Included children had directly supervised treatment and were then followed for 42 days with weekly clinical and parasitological evaluations. The blood samples of children found to have recurring parasitaemia within 42 days were checked by PCR to confirm whether or not this was due to reinfection or recrudescence (i.e. treatment failure). RESULTS: Out of 873 children screened, 585 (67 %) were excluded and 288 children were randomized to either ASAQ or AL. At day 42 of follow up, the treatment efficacy of ASAQ was 78 % before and 95 % after PCR correction for re-infections. In the AL-arm, treatment efficacy was 84 % before and 99.0 % after PCR correction. Treatment efficacy after PCR correction was within the margin of non-inferiority as set for this study. Fewer children in the AL arm reported adverse reactions. CONCLUSIONS: ASAQ is still effective as a treatment for uncomplicated malaria in Baraka, South Kivu, DRC. In this region, AL may have higher efficacy but additional trials are required to draw this conclusion with confidence. The high re-infection rate in South-Kivu indicates intense malaria transmission. Trial registration NCT02741024 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-016-1444-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5013565
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50135652016-09-08 In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo de Wit, Marit Funk, Anna L. Moussally, Krystel Nkuba, David Aksanti Siddiqui, Ruby Bil, Karla Piriou, Erwan Bart, Aldert Bahizi Bizoza, Patrick Bousema, Teun Malar J Research BACKGROUND: Between 2009 and 2012, malaria cases diagnosed in a Médecins sans Frontières programme have increased fivefold in Baraka, South Kivu, Democratic Republic of the Congo (DRC). The cause of this increase is not known. An in vivo drug efficacy trial was conducted to determine whether increased treatment failure rates may have contributed to the apparent increase in malaria diagnoses. METHODS: In an open-randomized non-inferiority trial, the efficacy of artesunate–amodiaquine (ASAQ) was compared to artemether–lumefantrine (AL) for the treatment of uncomplicated falciparum malaria in 288 children aged 6–59 months. Included children had directly supervised treatment and were then followed for 42 days with weekly clinical and parasitological evaluations. The blood samples of children found to have recurring parasitaemia within 42 days were checked by PCR to confirm whether or not this was due to reinfection or recrudescence (i.e. treatment failure). RESULTS: Out of 873 children screened, 585 (67 %) were excluded and 288 children were randomized to either ASAQ or AL. At day 42 of follow up, the treatment efficacy of ASAQ was 78 % before and 95 % after PCR correction for re-infections. In the AL-arm, treatment efficacy was 84 % before and 99.0 % after PCR correction. Treatment efficacy after PCR correction was within the margin of non-inferiority as set for this study. Fewer children in the AL arm reported adverse reactions. CONCLUSIONS: ASAQ is still effective as a treatment for uncomplicated malaria in Baraka, South Kivu, DRC. In this region, AL may have higher efficacy but additional trials are required to draw this conclusion with confidence. The high re-infection rate in South-Kivu indicates intense malaria transmission. Trial registration NCT02741024 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-016-1444-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-06 /pmc/articles/PMC5013565/ /pubmed/27599612 http://dx.doi.org/10.1186/s12936-016-1444-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
de Wit, Marit
Funk, Anna L.
Moussally, Krystel
Nkuba, David Aksanti
Siddiqui, Ruby
Bil, Karla
Piriou, Erwan
Bart, Aldert
Bahizi Bizoza, Patrick
Bousema, Teun
In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo
title In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo
title_full In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo
title_fullStr In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo
title_full_unstemmed In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo
title_short In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo
title_sort in vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in south kivu, democratic republic of congo
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013565/
https://www.ncbi.nlm.nih.gov/pubmed/27599612
http://dx.doi.org/10.1186/s12936-016-1444-x
work_keys_str_mv AT dewitmarit invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo
AT funkannal invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo
AT moussallykrystel invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo
AT nkubadavidaksanti invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo
AT siddiquiruby invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo
AT bilkarla invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo
AT piriouerwan invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo
AT bartaldert invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo
AT bahizibizozapatrick invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo
AT bousemateun invivoefficacyofartesunateamodiaquineandartemetherlumefantrineforthetreatmentofuncomplicatedfalciparummalariaanopenrandomizednoninferiorityclinicaltrialinsouthkivudemocraticrepublicofcongo